Brepocitinib clears skin in 69% with cutaneous sarcoidosis
In a 31-adult phase 2 trial, brepocitinib 45 mg produced clear or almost-clear skin in 69.2% at week 16, prompting a planned 140-patient phase 3 trial program.
Topic
Beacon Trial
Topic
Topic
Topic
In a 31-adult phase 2 trial, brepocitinib 45 mg produced clear or almost-clear skin in 69.2% at week 16, prompting a planned 140-patient phase 3 trial program.